ALS Investment Fund

About The Fund

ALS Investment Fund is a venture capital firm dedicated to advancing the field of biotechnology with a particular emphasis on combating Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease. They specialize in supporting and financing biotech companies that develop drugs and diagnostics, targeting neurodegenerative conditions, with a specific focus on ALS. They take pride in being a highly specialized investor within this niche, maintaining the largest and most diversified portfolio of ALS-related companies across the globe. Moreover, ALS Investment Fund is recognized as one of the most diversified venture capital funds in the realm of neurodegeneration more broadly, aiming to further expand its leadership in this sector. Their investment strategy involves funding companies from seed stage to Series A, with investment amounts ranging from a minimum of $100,000 to a maximum of $5,000,000, with a sweet spot of around $1,500,000 for investments. Through their significant portfolio and strong ties with an international network of scientists, clinicians, foundations, and patient advocates all focused on ALS, they are able to gather unique knowledge and create longstanding relationships that distinguish them from other investors. The fund's goal is to foster innovation and accelerate the development ofsolutions that not only target ALS but also neurodegenerative diseases more broadly, reflecting their dedication to improving healthcare outcomes and quality of life for individuals affected by these conditions.